(INNV) InnovAge Holding - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45784A1043

INNV: Medical Services, Home Care, Transportation, Meal Services, Therapy

InnovAge Holding Corp (NASDAQ:INNV) operates as a healthcare services provider specializing in senior care through the Program of All-Inclusive Care for the Elderly (PACE). The company delivers comprehensive medical and non-medical services to enable elderly participants to live independently in their homes or in supported community settings. Its service portfolio includes in-home care (skilled, unskilled, and personal care), in-center services such as primary care, physical therapy, and mental health services, as well as transportation to medical appointments. The company manages PACE centers across six states: Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. Formerly known as TCO Group Holdings, Inc., InnovAge rebranded in January 2021 and has been operational since its founding in 2007. The company is headquartered in Denver, Colorado.

From a financial perspective, InnovAge Holding Corp (NASDAQ:INNV) has a market capitalization of $449.01M USD. The stock currently trades at $3.26, with a 20-day average volume of 63,981 shares. Its price-to-book ratio stands at 1.81, and the forward P/E ratio is 13.66, indicating potential undervaluation relative to future earnings expectations. However, the return on equity (RoE) is -10.04%, reflecting current profitability challenges.

Over the next three months, based on the and , InnovAges stock is expected to remain volatile but range-bound. The 20-day moving average ($3.42) and 50-day moving average ($3.68) suggest downward momentum, while the 200-day moving average ($5.01) indicates longer-term weakness. The average true range (ATR) of 0.22 signals moderate price fluctuations. Given the negative RoE and the absence of a trailing P/E, investors may remain cautious. However, the forward P/E of 13.66 could attract value-oriented buyers if the company demonstrates operational improvements. Overall, the stock is likely to trade between $3.00 and $3.50, with potential downside risks tied to profitability concerns.

Additional Sources for INNV Stock

INNV Stock Overview

Market Cap in USD 403m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Services
IPO / Inception 2021-03-04

INNV Stock Ratings

Growth Rating -71.9
Fundamental -19.6
Dividend Rating 0.0
Rel. Strength -30.9
Analysts 2.75/5
Fair Price Momentum 2.04 USD
Fair Price DCF -

INNV Dividends

No Dividends Paid

INNV Growth Ratios

Growth Correlation 3m -87.3%
Growth Correlation 12m -55.1%
Growth Correlation 5y -59.3%
CAGR 5y -40.93%
CAGR/Max DD 5y -0.46
Sharpe Ratio 12m -0.07
Alpha -36.73
Beta 0.507
Volatility 57.48%
Current Volume 40.6k
Average Volume 20d 42.5k
What is the price of INNV stocks?
As of April 19, 2025, the stock is trading at USD 2.75 with a total of 40,600 shares traded.
Over the past week, the price has changed by -2.48%, over one month by -21.65%, over three months by -25.68% and over the past year by -31.25%.
Is InnovAge Holding a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, InnovAge Holding is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -19.55 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of INNV as of April 2025 is 2.04. This means that INNV is currently overvalued and has a potential downside of -25.82%.
Is INNV a buy, sell or hold?
InnovAge Holding has received a consensus analysts rating of 2.75. Therefor, it is recommend to hold INNV.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 3
  • Sell: 1
  • Strong Sell: 0
What are the forecast for INNV stock price target?
According to ValueRays Forecast Model, INNV InnovAge Holding will be worth about 2.2 in April 2026. The stock is currently trading at 2.75. This means that the stock has a potential downside of -19.27%.
Issuer Forecast Upside
Wallstreet Target Price 5.3 90.9%
Analysts Target Price 5.5 100%
ValueRay Target Price 2.2 -19.3%